These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27738644)

  • 1. Potential for cellular stress response to hepatic factor VIII expression from AAV vector.
    Zolotukhin I; Markusic DM; Palaschak B; Hoffman BE; Srikanthan MA; Herzog RW
    Mol Ther Methods Clin Dev; 2016; 3():16063. PubMed ID: 27738644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.
    Cao W; Dong B; Horling F; Firrman JA; Lengler J; Klugmann M; de la Rosa M; Wu W; Wang Q; Wei H; Moore AR; Roberts SA; Booth CJ; Hoellriegl W; Li D; Konkle B; Miao C; Reipert BM; Scheiflinger F; Rottensteiner H; Xiao W
    Mol Ther Methods Clin Dev; 2020 Dec; 19():486-495. PubMed ID: 33313336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice.
    Lange AM; Altynova ES; Nguyen GN; Sabatino DE
    Mol Ther Methods Clin Dev; 2016; 3():16064. PubMed ID: 27738645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.
    Markusic DM; Herzog RW
    J Genet Syndr Gene Ther; 2012 Jan; 1():1-9. PubMed ID: 23565343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
    Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
    Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.
    Samelson-Jones BJ; Arruda VR
    Mol Ther Methods Clin Dev; 2019 Mar; 12():184-201. PubMed ID: 30705923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.
    Brown HC; Wright JF; Zhou S; Lytle AM; Shields JE; Spencer HT; Doering CB
    Mol Ther Methods Clin Dev; 2014; 1():14036. PubMed ID: 26015976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A.
    Elkouby L; Armour SM; Toso R; DiPietro M; Davidson RJ; Nguyen GN; Willet M; Kutza S; Silverberg J; Frick J; Crosariol M; Wang Y; Wang C; High KA; Sabatino DE; Anguela XM
    Mol Ther Methods Clin Dev; 2022 Mar; 24():20-29. PubMed ID: 34977269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A.
    Lytle AM; Brown HC; Paik NY; Knight KA; Wright JF; Spencer HT; Doering CB
    Mol Ther Methods Clin Dev; 2016; 3():15056. PubMed ID: 26909355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice.
    Butterfield JSS; Yamada K; Bertolini TB; Syed F; Kumar SRP; Li X; Arisa S; Piñeros AR; Tapia A; Rogers CA; Li N; Rana J; Biswas M; Terhorst C; Kaufman RJ; de Jong YP; Herzog RW
    Mol Ther; 2022 Dec; 30(12):3552-3569. PubMed ID: 35821634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
    Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S
    Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular stress and coagulation factor production: when more is not necessarily better.
    Chen Z; Herzog RW; Kaufman RJ
    J Thromb Haemost; 2023 Dec; 21(12):3329-3341. PubMed ID: 37839613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.
    Siner JI; Samelson-Jones BJ; Crudele JM; French RA; Lee BJ; Zhou S; Merricks E; Raymer R; Nichols TC; Camire RM; Arruda VR
    JCI Insight; 2016 Oct; 1(16):e89371. PubMed ID: 27734034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of human factor VIII by splicing between dimerized AAV vectors.
    Chao H; Sun L; Bruce A; Xiao X; Walsh CE
    Mol Ther; 2002 Jun; 5(6):716-22. PubMed ID: 12027555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.